Analysts’ Viewpoint on Market Scenario
The global acute myeloid leukemia (AML) biomarker testing market is anticipated to witness promising growth from 2022 to 2031. Biomarker testing is utilized to detect and monitor the presence of specific biomarkers in the blood or bone marrow of a patient with AML. Rise in the incidence of AML is a major factor driving market expansion. Surge in the geriatric population is also expected to positively impact the demand for AML biomarker testing in the near future.
Approval and launch of novel companion diagnostic tests is projected to offer lucrative opportunities for key players in the industry. Vendors are focused on the R&D of new biomarkers to increase their acute myeloid leukemia (AML) biomarker testing market share.
Acute myeloid leukemia (AML) is a type of cancer that begins in the bone marrow and spreads throughout the body. It is not a single disease, but rather a group of blood disorders that develop in the myeloid cell line of bone marrow.
AML is caused by an excess of immature white blood cells (WBCs), known as myeloblasts or leukemic blasts. Myeloblast accumulates in the bone marrow, preventing it from producing normal blood cells. This disrupts the growth of other blood cells in the body, resulting in weakened immunity.
Biomarker testing is a vital tool for the diagnosis and management of AML, as it provides important information about the genetic makeup of cancer. According to the National Comprehensive Cancer Network (NCCN), the U.S. was projected to record 20,050 new AML cases, of which 11,180 were expected to be fatal.
Australia records more than 3,700 cases of leukemia annually. Around 1,400 of these cases are acute leukemia, accounting for about 1% of cancer cases in the country. Thus, high prevalence of AML is estimated to drive acute myeloid leukemia (AML) biomarker testing market growth in the near future.
Cancer incidence and mortality rates are higher in people aged 65 years and above than those in younger people. Around 60% of the cancer cases are recorded in the older age group, which is 10 to 11 times higher than that in the younger population. Therefore, rise in the geriatric population is expected to boost market dynamics in the next few years.
According to the World Health Organization (WHO), the global geriatric population is anticipated to grow from 962 million in 2017 to 1.4 billion in 2030. The global population of older people is projected to more than double to 2.1 billion by 2050. Asia Pacific is home to the majority of this age group. As per the United Nations Economic and Social Commission for Asia and the Pacific, around 60% of the world’s geriatric population lives in Asia Pacific.
According to the latest acute myeloid leukemia (AML) biomarker testing market analysis, the genetic segment accounted for major share in 2021. The segment is projected to dominate the industry during the forecast period.
Gene sequencing generally reveals more than 10 significant gene mutations; many of which are thought to participate in leukemogenesis. The most common gene mutations are as follows: FLT3 (28%), NPM1 (27%), DNMT3A (26%), IDH1 or IDH2 (20%), NRAS or KRAS (12%), RUNX1 (10%), TET2 (8%), TP53 (8%), CEBPA (6%), and WT1 (6%). Mutations impacting signal activation are frequent (60% of cases); the most common of which are mutations in FLT3.
According to the latest acute myeloid leukemia (AML) biomarker testing market trends, the PCR technology segment is projected to hold largest share during the forecast period. PCR provides several benefits including high sensitivity and specificity, rapid diagnosis, and effective monitoring of disease progression.
PCR-associated molecular testing methods take advantage of PCR amplification to make more copies of targeted DNA or RNA. Therefore, PCR-associated assays are usually more sensitive. PCR-associated assays can interrogate more specific genomic DNA changes with higher resolution than FISH assays.
North America is estimated to dominate the industry from 2022 to 2031. Presence of well-established healthcare and life science industries and early adoption of technologically advanced products are expected to drive market progress in the region. High awareness about AML and increase in healthcare expenditure are also likely to boost the demand for AML biomarker testing in the near future.
The industry in Asia Pacific is projected to grow at the highest CAGR of 9.1% during the forecast period. Surge in the incidence of AML and growth in government funding for R&D in disease diagnosis and treatment are anticipated to fuel market statistics in the region in the next few years.
Major vendors in the industry have been profiled in the acute myeloid leukemia (AML) biomarker testing market report based on parameters such as product portfolio, recent developments, financial overview, company overview, business strategies, and business segments.
These vendors include Abbott Laboratories, Bio-Rad Laboratories, Inc., Genmark Sağlık Ürünleri, Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH (Danaher), Medaysis Company, NeoGenomics Laboratories, QIAGEN N.V., and Thermo Fisher Scientific, Inc. Key players in the industry are focused on offering highly sensitive and specific biomarker tests to broaden their customer base.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 293.0 Mn |
|
Market Forecast Value in 2031 |
More than US$ 624.0 Mn |
|
Compound Annual Growth Rate (CAGR) |
8.0% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 293.0 Mn in 2021.
It is projected to reach a value of more than US$ 624.0 Mn by 2031.
It is expected to be 8.0% from 2022 to 2031.
Rise in incidence of acute myeloid leukemia and growth in geriatric population.
Abbott Laboratories, Bio-Rad Laboratories, Inc., Genmark Sağlık Ürünleri, Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH (Danaher), Medaysis Company, NeoGenomics Laboratories, QIAGEN N.V., and Thermo Fisher Scientific, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projection (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario by Region/Globally
5.3. Reimbursement Scenario by Region/Globally
5.4. AML Disease Prevalence & Incidence Rate in Key Countries
5.5. Acute Myeloid Leukemia (AML) Biomarker Assay Prices
5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long-term Impact)
6. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type of Biomarker, 2017–2031
6.3.1. Genetic
6.3.2. Protein
6.3.3. Others
6.4. Market Attractiveness Analysis, by Type of Biomarker
7. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technology, 2017–2031
7.3.1. NGS
7.3.2. PCR
7.3.3. Others
7.4. Market Attractiveness Analysis, by Technology
8. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-use, 2017–2031
8.3.1. Research Use Only
8.3.2. In Vitro Diagnostic Use
8.4. Market Attractiveness Analysis, by End-use
9. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type of Biomarker, 2017–2031
10.2.1. Genetic
10.2.2. Protein
10.2.3. Others
10.3. Market Value Forecast, by Technology, 2017–2031
10.3.1. NGS
10.3.2. PCR
10.3.3. Others
10.4. Market Value Forecast, by End-use, 2017–2031
10.4.1. Research Use Only
10.4.2. In Vitro Diagnostic Use
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type of Biomarker
10.6.2. By Technology
10.6.3. By End-use
10.6.4. By Country
11. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type of Biomarker, 2017–2031
11.2.1. Genetic
11.2.2. Protein
11.2.3. Others
11.3. Market Value Forecast, by Technology, 2017–2031
11.3.1. NGS
11.3.2. PCR
11.3.3. Others
11.4. Market Value Forecast, by End-use, 2017–2031
11.4.1. Research Use Only
11.4.2. In Vitro Diagnostic Use
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type of Biomarker
11.6.2. By Technology
11.6.3. By End-use
11.6.4. By Country/Sub-region
12. Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Biomarker, 2017–2031
12.2.1. Genetic
12.2.2. Protein
12.2.3. Others
12.3. Market Value Forecast, by Technology, 2017–2031
12.3.1. NGS
12.3.2. PCR
12.3.3. Others
12.4. Market Value Forecast, by End-use, 2017–2031
12.4.1. Research Use Only
12.4.2. In Vitro Diagnostic Use
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type of Biomarker
12.6.2. By Technology
12.6.3. By End-use
12.6.4. By Country/Sub-region
13. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Biomarker, 2017–2031
13.2.1. Genetic
13.2.2. Protein
13.2.3. Others
13.3. Market Value Forecast, by Technology, 2017–2031
13.3.1. NGS
13.3.2. PCR
13.3.3. Others
13.4. Market Value Forecast, by End-use, 2017–2031
13.4.1. Research Use Only
13.4.2. In Vitro Diagnostic Use
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type of Biomarker
13.6.2. By Technology
13.6.3. By End-use
13.6.4. By Country/Sub-region
14. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type of Biomarker, 2017–2031
14.2.1. Genetic
14.2.2. Protein
14.2.3. Others
14.3. Market Value Forecast, by Technology, 2017–2031
14.3.1. NGS
14.3.2. PCR
14.3.3. Others
14.4. Market Value Forecast, by End-use, 2017–2031
14.4.1. Research Use Only
14.4.2. In Vitro Diagnostic Use
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type of Biomarker
14.6.2. By Technology
14.6.3. By End-use
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Company Profiles
15.2.1. Abbott Laboratories
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. SWOT Analysis
15.2.1.4. Strategic Overview
15.2.2. Bio-Rad Laboratories, Inc.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Strategic Overview
15.2.3. Genmark Sağlık Ürünleri
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Strategic Overview
15.2.4. Laboratory Corporation of America Holdings
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. Leica Biosystems Nussloch GmbH (Danaher)
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. SWOT Analysis
15.2.5.4. Strategic Overview
15.2.6. Medaysis Company
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. SWOT Analysis
15.2.6.4. Strategic Overview
15.2.7. NeoGenomics Laboratories
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. SWOT Analysis
15.2.7.4. Strategic Overview
15.2.8. QIAGEN N.V.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. Thermo Fisher Scientific, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Strategic Overview
List of Table
Table 01: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
Table 02: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 03: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
Table 04: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
Table 07: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 08: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
Table 09: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
Table 10: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
Table 11: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 12: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
Table 13: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
Table 14: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
Table 15: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 16: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
Table 17: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
Table 19: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 20: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
Table 21: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
Table 23: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 24: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
List of Figures
Figure 01: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
Figure 03: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
Figure 04: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Genetic, 2017–2031
Figure 05: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Protein, 2017-2031
Figure 06: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Others, 2017-2031
Figure 07: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
Figure 08: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
Figure 09: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by NGS, 2017–2031
Figure 10: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by PCR, 2017-2031
Figure 11: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Others, 2017-2031
Figure 12: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
Figure 13: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
Figure 14: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Research Use Only, 2017–2031
Figure 15: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by In Vitro Diagnostic Use, 2017-2031
Figure 16: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Region, 2021 and 2031
Figure 17: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Region, 2022–2031
Figure 18: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 19: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country, 2021 and 2031
Figure 20: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country, 2022–2031
Figure 21: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
Figure 22: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
Figure 23: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
Figure 24: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
Figure 25: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
Figure 26: North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
Figure 27: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 28: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 29: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 30: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
Figure 31: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
Figure 32: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
Figure 33: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
Figure 34: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
Figure 35: Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
Figure 36: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 38: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 39: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
Figure 40: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
Figure 41: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
Figure 42: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
Figure 43: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
Figure 44: Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
Figure 45: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 47: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 48: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
Figure 49: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
Figure 50: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
Figure 51: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
Figure 52: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
Figure 53: Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
Figure 54: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 55: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 56: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 57: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
Figure 58: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
Figure 59: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
Figure 60: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
Figure 61: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
Figure 62: Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Acute Myeloid Leukemia (AML) Biomarker Testing Market
*86 figures and 60 tables includes